Psoriasis Drugs Market Size & Forecast by Therapeutic Class (Tumor Necrosis Factor-inhibitors, Interleukin-inhibitors, Vitamin D analogues), By Treatment (Topicals. Systemic, Biologics) And Trend Analysis from 2016 - 2022
The global psoriasis drugs market is expected to be valued at $21.4 billion by 2022, as per a new report by Grand View Research, Inc. The increasing number of reimbursement policies for treatment, advanced diagnostic tools, raised disease awareness and improved technological systems are likely to increase the adoption of therapeutics.
Additionally, the rising prevalence and incidence of psoriasis is anticipated to fuel the market growth. The condition has neither exact causes nor treatments to cure. Certain environmental and genetic factors may trigger the disease onset. Most treatments for the condition target to decelerate the severity of the disease by stopping the keratinocyte hyperproliferation. The disease symptoms can be managed by following a healthy lifestyle.
Further key findings from the report suggest:
Additionally, the rising prevalence and incidence of psoriasis is anticipated to fuel the market growth. The condition has neither exact causes nor treatments to cure. Certain environmental and genetic factors may trigger the disease onset. Most treatments for the condition target to decelerate the severity of the disease by stopping the keratinocyte hyperproliferation. The disease symptoms can be managed by following a healthy lifestyle.
Further key findings from the report suggest:
- Tumor Necrosis Factor-inhibitors dominated the psoriasis therapeutic market in 2016 owing to its higher usage by healthcare practitioners and easy availability.
- TNF-inhibitors are likely to lose market shares over the forecast period due to increasing adoption of IL-inhibitor therapy over conventional TNF-inhibitors
- Interleukin-inhibitors sector is expected to grow at lucrative CAGR of 19.4% over the forecast period because of improved safety and efficacy profiles of Interleukin-inhibiting drugs.
- The U.S. market is the dominant region in the psoriasis therapeutic space. It led the market in terms of revenue with $4.4 billion in 2016 due to the increasing number of patients seeking treatment and presence of well-established healthcare services.
- In addition, presence of several key manufacturers in the U.S. and launch of novel drugs are some of the factors anticipated to increase the demand for therapeutics in this region
- Japan is expected to be the fastest growing region over the next decade with lucrative CAGR of 13.0% from 2016 to 2022 due to growing awareness about the disease among the people. Furthermore, presence of a large target population and high unmet clinical needs are some of the factors expected to propel the growth of this region.
- Some of the key players in this industry are AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Eli Lilly & Company, AstraZeneca and Celgene Corporation.
- Most of the key players are focusing on strategies such as expansion of their product portfolios and collaborations, mergers, & acquisitions. The emergence of biosimilars is a rising trend adopted by these companies.
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information procurement
1.2 Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Disease Primer and Epidemiology
2.2 Global Market Overview
2.3 Product Pipeline
2.4 Competitive Landscape
2.5 Market Outlook
2.6 Market Snapshot
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1 Disease Primer
3.1.1 Types:
3.1.1.1 Plaque Psoriasis
3.1.1.2 Guttate Psoriasis
3.1.1.3 Inverse Psoriasis
3.1.1.4 Pustular Psoriasis
3.1.1.5 Erythrodermic Psoriasis
3.1.2 Pathophysiology
3.1.3 Complications
3.2 Epidemiology by indications
3.3 Current prevalence rate and numbers for 7 major markets (U.S., Japan, 5 E.U.)
3.4 Current incidence rate and numbers for 7 major markets (U.S., Japan, 5 E.U.)
3.5 Forecast prevalence and incidence for 7 major markets (U.S., Japan, 5 E.U.)
CHAPTER 4 GLOBAL MARKET OVERVIEW
4.1 Introduction and Market Overview
4.1.1 Market by Therapeutic Class
4.1.1.1 Tumour Necrosis Factor Inhibitors
4.1.1.1.1 Adalimumab
4.1.1.1.2 Infliximab
4.1.1.1.3 Etanercept
4.1.1.2 Interleukin-Inhibitors
4.1.1.2.1 Ustekinumab
4.1.1.2.2 Secukinumab
4.1.1.2.3 Ixekizumab
4.1.1.2.4 Brodalumab
4.1.1.3 Vitamin D analogues
4.1.1.3.1 Calcitriol
4.1.1.3.2 Calcipotriol
4.1.1.3.3 Tacalcitol
4.1.1.4 Others
4.1.2 Market by Treatment
4.1.2.1 Topicals
4.1.2.1.1 Over-the-counter (OTC) Topicals
4.1.2.1.2 Topical non-steroids
4.1.2.1.3 Topical Steroids
4.1.2.2 Systemic
4.1.2.2.1 Retinoid
4.1.2.2.2 Cyclosporine
4.1.2.2.3 Methotrexate
4.1.2.3 Biologics
4.1.2.3.1 Tumour necrosis factor alpha (TNF-?) inhibitors
4.1.2.3.2 Interleukin 12 and 23 (IL-12/23) inhibitors
4.1.2.3.3 Interleukin 17 (IL-17) inhibitor
4.1.2.3.4 T cell inhibitor
4.1.3 Market size & Forecast
4.1.4 Sales Performance
4.1.5 Market Share Distribution
4.1.6 Major Product Overview
4.1.6.1 Humira
4.1.6.2 Remicade
4.1.6.3 Enbrel
4.1.6.4 Stelara
4.1.6.5 Cosentyx
4.1.6.6 Taltz
4.1.6.7 Otezla
4.1.7 Market Dynamics among Leading Brands
4.2 Patent Expiry Analysis
4.3 Drivers and Challenges
4.4 M&A, Deal Landscape (2013-2017 YTD)
4.5 Pricing and Reimbursement Environment
4.6 Biosimilar Evolution (India, China, South Korea)
4.6.1 India
4.6.2 China
4.6.3 South Korea
4.7 Emerging Markets
4.8 SWOT Analysis
CHAPTER 5 PRODUCT PIPELINE
5.1 Pipeline Landscape
5.1.1 Leading drugs in development
5.1.1.1 Mode of Approach: Injectables
5.1.1.2 Mode of Approach: Oral
5.1.1.3 Mode of Approach: Topical
5.1.1.4 Mode of Approach: Biosimilar
5.1.2 Key R&D Trends
5.2 Promising Drug Candidates in Pipeline
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profile of disruptive drugs
5.2.2.1 GP2015 (Erelzi)
5.2.2.2 GP2017
5.2.2.3 ABP501 (Amjevita)
5.2.2.4 BI 655066
5.2.2.5 Cimzia
5.2.2.6 Tildrakizumab
5.2.2.7 BI695501
CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 AbbVie Inc.
6.1.1 Company overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales up to 2022
6.1.4 Strategic initiatives(Humira)
6.1.5 Company - Key News Flow
6.1.6 Pipeline View
6.1.7 Pipeline Forecast
6.1.8 Catalysts and Event Calendar
6.1.9 SWOT Analysis
6.2 Amgen, Inc.
6.2.1 Company overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales up to 2022
6.2.4 Strategic initiatives(Enbrel)
6.2.5 Company - Key News Flow
6.2.6 Pipeline View
6.2.7 Pipeline Forecast
6.2.8 Catalysts and Event Calendar
6.2.9 SWOT Analysis
6.3 Johnson & Johnson
6.3.1 Company overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales up to 2022
6.3.4 Strategic initiatives
6.3.4.1 Remicade
6.3.4.2 Stelara
6.3.4.3 Tremfya
6.3.5 Company - Key News Flow
6.3.6 Pipeline View
6.3.7 Pipeline Forecast
6.3.8 Catalysts and Event Calendar
6.3.9 SWOT Analysis
6.4 Novartis AG
6.4.1 Company overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales up to 2022
6.4.4 Strategic initiatives(Cosentyx)
6.4.5 Company - Key News Flow
6.4.6 Pipeline View
6.4.7 Pipeline Forecast
6.4.8 Catalysts and Event Calendar
6.4.9 SWOT Analysis
6.5 Eli Lilly and Company
6.5.1 Company overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales up to 2022
6.5.4 Strategic initiatives(Taltz)
6.5.5 Company - Key News Flow
6.5.6 Pipeline View
6.5.7 Pipeline Forecast
6.5.8 Catalysts and Event Calendar
6.5.9 SWOT Analysis
6.6 AstraZeneca
6.6.1 Company overview
6.6.2 Current Product Portfolio
6.6.3 Strategic initiatives(Siliq)
6.6.4 Company - Key News Flow
6.6.5 Pipeline View
6.6.6 Pipeline Forecast
6.6.7 Catalysts and Event Calendar
6.6.8 SWOT Analysis
6.7 Celgene Corporation
6.7.1 Company overview
6.7.2 Current Product Portfolio
6.7.3 Product Forecast Sales up to 2022
6.7.4 Strategic initiatives(Otezla)
6.7.5 Company - Key News Flow
6.7.6 Pipeline View
6.7.7 Pipeline Forecast
6.7.8 Catalysts and Event Calendar
6.7.9 SWOT Analysis
CHAPTER 7 MARKET OUTLOOK
7.1 What the future holds
7.2 Winners and Losers
7.3 Emerging Companies
7.4 The road ahead
1.1 Information procurement
1.2 Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Disease Primer and Epidemiology
2.2 Global Market Overview
2.3 Product Pipeline
2.4 Competitive Landscape
2.5 Market Outlook
2.6 Market Snapshot
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1 Disease Primer
3.1.1 Types:
3.1.1.1 Plaque Psoriasis
3.1.1.2 Guttate Psoriasis
3.1.1.3 Inverse Psoriasis
3.1.1.4 Pustular Psoriasis
3.1.1.5 Erythrodermic Psoriasis
3.1.2 Pathophysiology
3.1.3 Complications
3.2 Epidemiology by indications
3.3 Current prevalence rate and numbers for 7 major markets (U.S., Japan, 5 E.U.)
3.4 Current incidence rate and numbers for 7 major markets (U.S., Japan, 5 E.U.)
3.5 Forecast prevalence and incidence for 7 major markets (U.S., Japan, 5 E.U.)
CHAPTER 4 GLOBAL MARKET OVERVIEW
4.1 Introduction and Market Overview
4.1.1 Market by Therapeutic Class
4.1.1.1 Tumour Necrosis Factor Inhibitors
4.1.1.1.1 Adalimumab
4.1.1.1.2 Infliximab
4.1.1.1.3 Etanercept
4.1.1.2 Interleukin-Inhibitors
4.1.1.2.1 Ustekinumab
4.1.1.2.2 Secukinumab
4.1.1.2.3 Ixekizumab
4.1.1.2.4 Brodalumab
4.1.1.3 Vitamin D analogues
4.1.1.3.1 Calcitriol
4.1.1.3.2 Calcipotriol
4.1.1.3.3 Tacalcitol
4.1.1.4 Others
4.1.2 Market by Treatment
4.1.2.1 Topicals
4.1.2.1.1 Over-the-counter (OTC) Topicals
4.1.2.1.2 Topical non-steroids
4.1.2.1.3 Topical Steroids
4.1.2.2 Systemic
4.1.2.2.1 Retinoid
4.1.2.2.2 Cyclosporine
4.1.2.2.3 Methotrexate
4.1.2.3 Biologics
4.1.2.3.1 Tumour necrosis factor alpha (TNF-?) inhibitors
4.1.2.3.2 Interleukin 12 and 23 (IL-12/23) inhibitors
4.1.2.3.3 Interleukin 17 (IL-17) inhibitor
4.1.2.3.4 T cell inhibitor
4.1.3 Market size & Forecast
4.1.4 Sales Performance
4.1.5 Market Share Distribution
4.1.6 Major Product Overview
4.1.6.1 Humira
4.1.6.2 Remicade
4.1.6.3 Enbrel
4.1.6.4 Stelara
4.1.6.5 Cosentyx
4.1.6.6 Taltz
4.1.6.7 Otezla
4.1.7 Market Dynamics among Leading Brands
4.2 Patent Expiry Analysis
4.3 Drivers and Challenges
4.4 M&A, Deal Landscape (2013-2017 YTD)
4.5 Pricing and Reimbursement Environment
4.6 Biosimilar Evolution (India, China, South Korea)
4.6.1 India
4.6.2 China
4.6.3 South Korea
4.7 Emerging Markets
4.8 SWOT Analysis
CHAPTER 5 PRODUCT PIPELINE
5.1 Pipeline Landscape
5.1.1 Leading drugs in development
5.1.1.1 Mode of Approach: Injectables
5.1.1.2 Mode of Approach: Oral
5.1.1.3 Mode of Approach: Topical
5.1.1.4 Mode of Approach: Biosimilar
5.1.2 Key R&D Trends
5.2 Promising Drug Candidates in Pipeline
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profile of disruptive drugs
5.2.2.1 GP2015 (Erelzi)
5.2.2.2 GP2017
5.2.2.3 ABP501 (Amjevita)
5.2.2.4 BI 655066
5.2.2.5 Cimzia
5.2.2.6 Tildrakizumab
5.2.2.7 BI695501
CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 AbbVie Inc.
6.1.1 Company overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales up to 2022
6.1.4 Strategic initiatives(Humira)
6.1.5 Company - Key News Flow
6.1.6 Pipeline View
6.1.7 Pipeline Forecast
6.1.8 Catalysts and Event Calendar
6.1.9 SWOT Analysis
6.2 Amgen, Inc.
6.2.1 Company overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales up to 2022
6.2.4 Strategic initiatives(Enbrel)
6.2.5 Company - Key News Flow
6.2.6 Pipeline View
6.2.7 Pipeline Forecast
6.2.8 Catalysts and Event Calendar
6.2.9 SWOT Analysis
6.3 Johnson & Johnson
6.3.1 Company overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales up to 2022
6.3.4 Strategic initiatives
6.3.4.1 Remicade
6.3.4.2 Stelara
6.3.4.3 Tremfya
6.3.5 Company - Key News Flow
6.3.6 Pipeline View
6.3.7 Pipeline Forecast
6.3.8 Catalysts and Event Calendar
6.3.9 SWOT Analysis
6.4 Novartis AG
6.4.1 Company overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales up to 2022
6.4.4 Strategic initiatives(Cosentyx)
6.4.5 Company - Key News Flow
6.4.6 Pipeline View
6.4.7 Pipeline Forecast
6.4.8 Catalysts and Event Calendar
6.4.9 SWOT Analysis
6.5 Eli Lilly and Company
6.5.1 Company overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales up to 2022
6.5.4 Strategic initiatives(Taltz)
6.5.5 Company - Key News Flow
6.5.6 Pipeline View
6.5.7 Pipeline Forecast
6.5.8 Catalysts and Event Calendar
6.5.9 SWOT Analysis
6.6 AstraZeneca
6.6.1 Company overview
6.6.2 Current Product Portfolio
6.6.3 Strategic initiatives(Siliq)
6.6.4 Company - Key News Flow
6.6.5 Pipeline View
6.6.6 Pipeline Forecast
6.6.7 Catalysts and Event Calendar
6.6.8 SWOT Analysis
6.7 Celgene Corporation
6.7.1 Company overview
6.7.2 Current Product Portfolio
6.7.3 Product Forecast Sales up to 2022
6.7.4 Strategic initiatives(Otezla)
6.7.5 Company - Key News Flow
6.7.6 Pipeline View
6.7.7 Pipeline Forecast
6.7.8 Catalysts and Event Calendar
6.7.9 SWOT Analysis
CHAPTER 7 MARKET OUTLOOK
7.1 What the future holds
7.2 Winners and Losers
7.3 Emerging Companies
7.4 The road ahead
LIST OF TABLES
TABLE 1 Current prevalence rates and numbers across 7 major markets - 2016
TABLE 2 Current incidence rates and numbers across 7 major markets - 2016
TABLE 3 Forecast global prevalence 2016 - 2022
TABLE 4 Forecast global incidence 2016 - 2022
TABLE 5 Forecast prevalence for 7 major markets 2016 - 2022
TABLE 6 Forecast incidence for 7 major markets 2016 - 2022
TABLE 7 Psoriasis therapeutics market size and forecast
TABLE 8 Geographic sales performance of psoriasis therapeutics by region
TABLE 9 Psoriasis therapeutic market by drug class
TABLE 10 Forecast sales of leading brands in the global psoriasis market
TABLE 11 Global psoriasis pipeline forecast
TABLE 12 Global psoriasis pipeline sales forecast
TABLE 13 Psoriasis sales forecast by company
TABLE 14 Psoriasis therapeutic market share by company
TABLE 15 Patent Expiry Analysis
TABLE 16 M&A, Deal Landscape
TABLE 17 Mode of Approach: Injectables
TABLE 18 Mode of Approach: Oral
TABLE 19 Mode of Approach: Topical
TABLE 20 Mode of Approach: Biosimilar
TABLE 21 Late-stage pipeline and sales forecast
TABLE 22 Product Profile: GP2015 (Erelzi)
TABLE 23 Product Profile: GP2017
TABLE 24 Product Profile: ABP501 (Amjevita)
TABLE 25 Product Profile: BI655066
TABLE 26 Product Profile: Cimzia
TABLE 27 Product Profile: Tildrakizumab
TABLE 28 Product Profile: BI695501
TABLE 29 Product Portfolio: Humira
TABLE 30 Humira forecast sales up to 2022
TABLE 31 AbbVie pipeline view
TABLE 32 AbbVie catalysts and event calendar
TABLE 33 Product Portfolio: Enbrel
TABLE 34 Enbrel forecast sales up to 2022
TABLE 35 Amgen pipeline view
TABLE 36 Amgen catalysts and event calendar
TABLE 37 Product Portfolio: Remicade
TABLE 38 Product Portfolio: Stelara
TABLE 39 Product Portfolio: Tremfya
TABLE 40 Remicade product forecast sales upto 2022
TABLE 41 Stelara product forecast sales upto 2022
TABLE 42 Tremfya product forecast sales upto 2022
TABLE 43 Johnson & Johnson pipeline view
TABLE 44 Johnson & Johnson catalysts and event calendar
TABLE 45 Product Portfolio: Cosentyx
TABLE 46 Cosentyx product forecast sales upto 2022
TABLE 47 Novartis pipeline view
TABLE 48 Novartis catalysts and event calendar
TABLE 49 Product Portfolio: Taltz
TABLE 50 Taltz forecast sales up to 2022
TABLE 51 Eli Lilly pipeline view
TABLE 52 Eli Lilly catalysts and event calendar
TABLE 53 Product Portfolio: Siliq
TABLE 54 AstraZeneca pipeline view
TABLE 55 AstraZeneca catalysts and event calendar
TABLE 56 Product Portfolio: Otezla
TABLE 57 Otezla forecast sales up to 2022
TABLE 58 Celgene pipeline view
TABLE 59 Celgene catalysts and event calenadar
TABLE 1 Current prevalence rates and numbers across 7 major markets - 2016
TABLE 2 Current incidence rates and numbers across 7 major markets - 2016
TABLE 3 Forecast global prevalence 2016 - 2022
TABLE 4 Forecast global incidence 2016 - 2022
TABLE 5 Forecast prevalence for 7 major markets 2016 - 2022
TABLE 6 Forecast incidence for 7 major markets 2016 - 2022
TABLE 7 Psoriasis therapeutics market size and forecast
TABLE 8 Geographic sales performance of psoriasis therapeutics by region
TABLE 9 Psoriasis therapeutic market by drug class
TABLE 10 Forecast sales of leading brands in the global psoriasis market
TABLE 11 Global psoriasis pipeline forecast
TABLE 12 Global psoriasis pipeline sales forecast
TABLE 13 Psoriasis sales forecast by company
TABLE 14 Psoriasis therapeutic market share by company
TABLE 15 Patent Expiry Analysis
TABLE 16 M&A, Deal Landscape
TABLE 17 Mode of Approach: Injectables
TABLE 18 Mode of Approach: Oral
TABLE 19 Mode of Approach: Topical
TABLE 20 Mode of Approach: Biosimilar
TABLE 21 Late-stage pipeline and sales forecast
TABLE 22 Product Profile: GP2015 (Erelzi)
TABLE 23 Product Profile: GP2017
TABLE 24 Product Profile: ABP501 (Amjevita)
TABLE 25 Product Profile: BI655066
TABLE 26 Product Profile: Cimzia
TABLE 27 Product Profile: Tildrakizumab
TABLE 28 Product Profile: BI695501
TABLE 29 Product Portfolio: Humira
TABLE 30 Humira forecast sales up to 2022
TABLE 31 AbbVie pipeline view
TABLE 32 AbbVie catalysts and event calendar
TABLE 33 Product Portfolio: Enbrel
TABLE 34 Enbrel forecast sales up to 2022
TABLE 35 Amgen pipeline view
TABLE 36 Amgen catalysts and event calendar
TABLE 37 Product Portfolio: Remicade
TABLE 38 Product Portfolio: Stelara
TABLE 39 Product Portfolio: Tremfya
TABLE 40 Remicade product forecast sales upto 2022
TABLE 41 Stelara product forecast sales upto 2022
TABLE 42 Tremfya product forecast sales upto 2022
TABLE 43 Johnson & Johnson pipeline view
TABLE 44 Johnson & Johnson catalysts and event calendar
TABLE 45 Product Portfolio: Cosentyx
TABLE 46 Cosentyx product forecast sales upto 2022
TABLE 47 Novartis pipeline view
TABLE 48 Novartis catalysts and event calendar
TABLE 49 Product Portfolio: Taltz
TABLE 50 Taltz forecast sales up to 2022
TABLE 51 Eli Lilly pipeline view
TABLE 52 Eli Lilly catalysts and event calendar
TABLE 53 Product Portfolio: Siliq
TABLE 54 AstraZeneca pipeline view
TABLE 55 AstraZeneca catalysts and event calendar
TABLE 56 Product Portfolio: Otezla
TABLE 57 Otezla forecast sales up to 2022
TABLE 58 Celgene pipeline view
TABLE 59 Celgene catalysts and event calenadar
LIST OF FIGURES
FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary, 2016
FIG. 8 Current prevalence rates and numbers across 7 major markets - 2016
FIG. 9 Current incidence rates and numbers across 7 major markets - 2016
FIG. 10 Global psoriasis epidemiology 2016 - 2022
FIG. 11 Market segmentation & scope
FIG. 12 Psoriasis therapeutic market by drug class
FIG. 13 Psoriasis market share by company 2016 - 2022
FIG. 14 Market trends & outlook
FIG. 15 Market driver relevance analysis (Current & future impact)
FIG. 16 Market restraint relevance analysis (Current & future impact)
FIG. 17 SWOT Analysis (Psoriasis therapeutic sector)
FIG. 18 SWOT Analysis (AbbVie)
FIG. 19 SWOT Analysis (Amgen)
FIG. 20 SWOT Analysis (Johnson & Johnson)
FIG. 21 SWOT Analysis (Novartis)
FIG. 22 SWOT Analysis (Eli Lilly)
FIG. 23 SWOT Analysis (AstraZeneca)
FIG. 24 SWOT Analysis (Celgene)
FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary, 2016
FIG. 8 Current prevalence rates and numbers across 7 major markets - 2016
FIG. 9 Current incidence rates and numbers across 7 major markets - 2016
FIG. 10 Global psoriasis epidemiology 2016 - 2022
FIG. 11 Market segmentation & scope
FIG. 12 Psoriasis therapeutic market by drug class
FIG. 13 Psoriasis market share by company 2016 - 2022
FIG. 14 Market trends & outlook
FIG. 15 Market driver relevance analysis (Current & future impact)
FIG. 16 Market restraint relevance analysis (Current & future impact)
FIG. 17 SWOT Analysis (Psoriasis therapeutic sector)
FIG. 18 SWOT Analysis (AbbVie)
FIG. 19 SWOT Analysis (Amgen)
FIG. 20 SWOT Analysis (Johnson & Johnson)
FIG. 21 SWOT Analysis (Novartis)
FIG. 22 SWOT Analysis (Eli Lilly)
FIG. 23 SWOT Analysis (AstraZeneca)
FIG. 24 SWOT Analysis (Celgene)
